Evotaz, a combination drug consisting of the protease inhibitor atazanavir (Reyataz) and the pharmacoenhancer cobicistat (Tybost), has been launched by Bristol-Myers Squibb.
Further information
View Evotaz drug record
Summary of Product Characteristics
Manufacturer: Bristol-Myers Squibb
The 300mg/150mg tablets are licensed in combination with other antiretrovirals for the treatment of HIV-1 infected patients without known mutations associated with atazanavir resistance.